Skip to main content
. 2023 Nov 3;9(1):134–144. doi: 10.1016/j.ekir.2023.10.023

Table 1.

Comparison of patients’ characteristics before and after imputation

Characteristics Missing Data (%) Before Imputation After Imputation P-Value
Age (yrs) 0 59 (40–70) No imputation -
Gender (%) 0 M: 69.6 No imputation -
Weight (kg) 3.3 75 (68.4–84) 74.8 (68.4–84.0) 0.95
Height (cm) 6.5 172 (165–178) 172 (165–178) 1.0
Use of
  • -

    angiotensin-converting enzyme inhibitors (%)

  • -

    angiotensin II receptors blockers (%)

  • -

    furosemide (%)

  • -

    hydrochlorothiazide (%)
  • -

    9.8

  • -

    9.8

  • -

    13.0

  • -

    12.0
  • -

    Yes: 63.9/ No: 36.1

  • -

    Yes: 59.0/ No: 41.0

  • -

    Yes: 76.2/ No: 23.8

  • -

    Yes: 24.7/ No: 75.3
  • -

    Yes: 63.0/ No: 37.0

  • -

    Yes: 62.0/ No: 38.0

  • -

    Yes: 78.3/ No: 21.7

  • -

    Yes: 25.0/ No: 75.0

  • 0.90

  • 0.16

  • 0.41

  • 1.0
Categorical rituximab concentrations (%) 0 <2 μg/ml: 59.8
≥2 μg/ml: 40.2		 No imputation -
Proteinuria (g/g)
  • -

    on day-0

 0 5.7 (4.1–7.8) No imputation -
  • -

    on day-15

 23.9 4.9 (3.0–7.9) 5.4 (3.2–7.8) 0.65
Serum albumin (g/l)
  • -

    on day-0

 0 22.0 (17.0–29.0) No imputation -
  • -

    on day-15

 23.9 22.4 (18.0–28.4) 22.7 (18.8–27.9) 0.95
Serum creatinine (μmol/l)
  • -

    on day-0

 2.2 120.0 (88.2–149.0) 120.0 (88.8–149.0) 0.91
  • -

    on day-15

 20.7 118.0 (97.0–158.0) 118.0 (97.0–158.0) 0.98
Glomerular filtration rate estimated by CKD-EPI formula (ml/min per 1.73 m2)
  • -

    on day-0

 9.8 53 (40–73) 54 (40–71) 0.87
  • -

    on day-15

 21.7 55 (34–74) 57 (40–73) 0.68
CD19+ cell count (cells/μl) on day-0 26.1 169.0 (85.8–261.0) 188.0 (116.0–209.0) 0.72
Anti-PLA2R1 antibody titer (RU/ml) on day-0 9.8 95.0 (40.5–217.0) 114.0 (47.8–212.0) 0.77

CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; PLA2R1, phospholipase A2 receptor type 1.

The data are presented as median (Interquartile range). The comparisons of data imputation were performed using Wilcoxon test (quantitative) and chi-square test (qualitative).